0000899243-19-023912.txt : 20190919 0000899243-19-023912.hdr.sgml : 20190919 20190919160527 ACCESSION NUMBER: 0000899243-19-023912 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190917 FILED AS OF DATE: 20190919 DATE AS OF CHANGE: 20190919 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ENRIGHT PATRICK G CENTRAL INDEX KEY: 0001253886 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37519 FILM NUMBER: 191101819 MAIL ADDRESS: STREET 1: CO LONGITUDE CAPITAL PARTNERS LLC STREET 2: 800 EL CAMINO REAL, SUITE 220 CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc. CENTRAL INDEX KEY: 0001631650 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452748244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 BUSINESS PHONE: (650) 614-5220 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 FORMER COMPANY: FORMER CONFORMED NAME: Allergen Research Corp DATE OF NAME CHANGE: 20150123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-09-17 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001253886 ENRIGHT PATRICK G C/O LONGITUDE CAPITAL PARTNERS II, LLC 2740 SAND HILL ROAD, SECOND FLOOR MENLO PARK CA 94025 1 0 0 0 Common Stock, $0.0001 par value 2019-09-17 4 A 0 12500 22.3373 A 45561 D Common Stock, $0.0001 par value 6013134 I By: LVP2 The price reported in Column 4 is a weighted price. These Shares were purchased in multiple transactions at prices ranging from $22.28 to $22.42 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote. Reflects shares held by Longitude Venture Partners II, L.P. ("LVP2"). Longitude Capital Partners II, LLC ("LCP2") is the general partner of LVP2 and may be deemed to share voting and investment power over the shares of the Issuer held by LVP2. Patrick G. Enright is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LVP2. Mr. Enright disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. /s/ Douglas T. Sheehy, as Attorney-in-Fact for Patrick G. Enright 2019-09-19